A
Antonio Craxì
Researcher at University of Palermo
Publications - 699
Citations - 44773
Antonio Craxì is an academic researcher from University of Palermo. The author has contributed to research in topics: Hepatitis C & Cirrhosis. The author has an hindex of 86, co-authored 659 publications receiving 39463 citations. Previous affiliations of Antonio Craxì include University of Pavia & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
HBV recurrence after HCV clearance on DAAs: Sometimes they come back.
Vincenza Calvaruso,Antonio Craxì +1 more
Journal ArticleDOI
Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort
Vincenza Calvaruso,Salvatore Petta,Irene Cacciola,Giuseppe Cabibbo,Cerri Fabio,M.A. Di Rosolini,A. Davì,M.R. Cannavò,Maurizio Russello,M. Di Stefano,G. Scifo,F. Di Lorenzo,P. Tullio,L. Larocca,A. Montineri,G. Fuduli,A. Di Giacomo,M. Cannizzaro,S. Madonia,Anna Licata,Giuseppe Malizia,Giuseppe Alaimo,Gaetano Bertino,Bruno Cacopardo,Carmelo Iacobello,A. Averna,L. Guarneri,I. Scalisi,Giovanni Mazzola,Luigi Mondello,P. Vincenzo,Giovanni Squadrito,Calogero Cammà,G. Raimondo,Antonio Craxì,V. Di Marco +35 more
Journal ArticleDOI
PEG IFN alfa-2a vs. alfa-2b: And the winner is …?
TL;DR: In patients infected with HCV genotype 1, the rates of sustained virologic response and tolerability did not differ significantly between the two available peginterferon–ribavirin regimens.
Journal ArticleDOI
Analysis of hemochromatosis gene mutations in the Sicilian population: implications for survival and longevity.
Carmela Rita Balistreri,Giuseppina Candore,P.L. Almasio,V. Di Marco,Giuseppina Colonna-Romano,Antonio Craxì,Massimo Motta,Giuseppina Piazza,Mariano Malaguarnera,Domenico Lio,Calogero Caruso +10 more
Journal ArticleDOI
The dilemma for patients with chronic hepatitis C: treat now or warehouse?
TL;DR: Dual therapy with peginterferon and ribavirin, the only treatent for chronic hepatitis C available in Italy and in many other ountries worldwide up to 2013, obtains satisfactory response in infections with hepatitis C virus (HCV) genotype 2, but far rom optimal for other genotypes.